% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • muckfiddler muckfiddler Oct 26, 2013 12:17 PM Flag

    not great...

    results seems to keep deteriorating...I'm sure AF will a word or two to say....we'll see what happens monday but nothing very upbeat about these results.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Lol this is a cancer that kills everyone within 1 year. Super aggressive and super fast. We increased median OS by 3 months or nearly 50 percent compared to standard of care. On a very hard to treat cancer. And it works on 15 plus other types of cancer. What did you expect. These people would be cured?

      For less aggressive types of cancer you can similarly expect anywhere from 50 percent improved results over standard of care to complete cure.

      All the big boys are here because the science is solid. We were best of ASCO bc the science is solid. We will have statistical significance off of the phase 3 without an issue.

      What part of the results continue to get better as the study goes on dont you understand?

      Also AF is an idiot and says everything will fail except SRPT haha

    • I think the market will decide on Monday.

      Sentiment: Hold

    • who af
      a phd
      a nobel prize winner
      I think u have a problem if that is youre guru

    • sounds like you're on the wrong side of the trade and hoping AF will bash the stock for you, cover pre market on mondayif you get the chance

      Sentiment: Strong Buy

    • where do u see that?

    • Are you coming from another planet? The results are as follows:

      -Median overall survival was 10.7 months for ganetespib and docetaxel versus 7.4 months for docetaxel alone.
      -Overall survival Hazard Ratio in the chemosensitive population was 0.75 (90% CI 0.56, 1.03; 1-sided p=0.065) and 0.72 (90% C.I. 0.52, 0.98; 1-sided p=0.040) in the Cox proportional hazards univariate (unadjusted) and multivariate (adjusted) models, respectively.
      -The safety profile of patients treated with the combination of ganetespib (G) and docetaxel (D) was generally similar to that of docetaxel alone, consistent with previously reported results.

      “'As the data become more mature, the improvements in progression-free survival and overall survival with ganetespib and docetaxel in the patient subpopulation selected for Phase 3 study are very encouraging,” said Dr. Suresh Ramalingam, M.D., Professor, Hematology & Medical Oncology, and Director, Division of Medical Oncology, of the Winship Cancer Institute of Emory University, and a principal investigator of the GALAXY program. “These results bode well for the mirror image GALAXY-2 trial.”

1.98+0.01(+0.51%)Oct 12 4:00 PMEDT